Silver Book Fact

Full medication coverage is expected to increase patient compliance from 50% to 76%. Expanded coverage would cost insurers an average of $644 more per patient, but would avert an average of $6,770 in event-related costs. Insurers would ultimately save $5,974 per patient.

Choudhry N, Avorn J, Antman E, Schneeweiss S, et al. Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An economic analysis. Health Affairs. 2007; 26(1): 186-194. https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.26.1.186?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed

Reference

Title
Should Patients Receive Secondary Prevention Medications For Free After A Myocardial Infarction? An economic analysis
Publication
Health Affairs
Publisher
Project HOPE
Publication Date
2007
Authors
Choudhry N, Avorn J, Antman E, Schneeweiss S, et al.
Volume & Issue
Volume 26, Issue 1
Pages
186-194
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • The use of ACE inhibitors in hypertensive patients 80 years of older was associated in this study with a 30% reduction in the rate of stroke and a 64% reduction…  
  • Life expectancy and quality of life gains from AVR
    A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years…  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Survival rates of patients ages 65-75 with valve repair and replacement